Cargando…

Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease

Patients with sickle cell disease (SCD) are at increased risk for invasive pneumococcal disease because of splenic dysfunction. To mitigate this risk, patients are protected with prophylactic penicillin until completion of pneumococcal vaccination series. The objective of this study was to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahim, Mahvish Q., Arends, Alexandria M., Jacob, Seethal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728750/
https://www.ncbi.nlm.nih.gov/pubmed/33974588
http://dx.doi.org/10.1097/MPH.0000000000002187
_version_ 1784626795438407680
author Rahim, Mahvish Q.
Arends, Alexandria M.
Jacob, Seethal A.
author_facet Rahim, Mahvish Q.
Arends, Alexandria M.
Jacob, Seethal A.
author_sort Rahim, Mahvish Q.
collection PubMed
description Patients with sickle cell disease (SCD) are at increased risk for invasive pneumococcal disease because of splenic dysfunction. To mitigate this risk, patients are protected with prophylactic penicillin until completion of pneumococcal vaccination series. The objective of this study was to assess the maintenance of a protective immune response to pneumococcal vaccination in children with SCD. A retrospective review was conducted between June 2019 and June 2020 of all patients with SCD patients for whom it had been 5±1 year since completion of PPSV23 vaccination series. A total of 41 patients were analyzed. The majority of children (68%) were able to maintain an adequate immune response. There was no identifiable disease characteristic associated with maintenance of an appropriate immunogenic response. This study finds that patients with SCD are able to maintain an adequate immune response at the 5±1 year time point from completion of PPSV23 vaccination series. Similarly, patients were not found to have an increased rate of invasive pneumococcal disease even if not meeting criteria for adequate pneumococcal serum titer levels. Maintenance of pneumococcal titers suggests that there may not be a need for revaccination at the 5-year time point in this patient population.
format Online
Article
Text
id pubmed-8728750
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87287502022-01-07 Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease Rahim, Mahvish Q. Arends, Alexandria M. Jacob, Seethal A. J Pediatr Hematol Oncol Online Articles: Original Articles Patients with sickle cell disease (SCD) are at increased risk for invasive pneumococcal disease because of splenic dysfunction. To mitigate this risk, patients are protected with prophylactic penicillin until completion of pneumococcal vaccination series. The objective of this study was to assess the maintenance of a protective immune response to pneumococcal vaccination in children with SCD. A retrospective review was conducted between June 2019 and June 2020 of all patients with SCD patients for whom it had been 5±1 year since completion of PPSV23 vaccination series. A total of 41 patients were analyzed. The majority of children (68%) were able to maintain an adequate immune response. There was no identifiable disease characteristic associated with maintenance of an appropriate immunogenic response. This study finds that patients with SCD are able to maintain an adequate immune response at the 5±1 year time point from completion of PPSV23 vaccination series. Similarly, patients were not found to have an increased rate of invasive pneumococcal disease even if not meeting criteria for adequate pneumococcal serum titer levels. Maintenance of pneumococcal titers suggests that there may not be a need for revaccination at the 5-year time point in this patient population. Lippincott Williams & Wilkins 2022-01 2021-05-11 /pmc/articles/PMC8728750/ /pubmed/33974588 http://dx.doi.org/10.1097/MPH.0000000000002187 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Online Articles: Original Articles
Rahim, Mahvish Q.
Arends, Alexandria M.
Jacob, Seethal A.
Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease
title Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease
title_full Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease
title_fullStr Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease
title_full_unstemmed Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease
title_short Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease
title_sort maintenance of an immunogenic response to pneumococcal vaccination in children with sickle cell disease
topic Online Articles: Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728750/
https://www.ncbi.nlm.nih.gov/pubmed/33974588
http://dx.doi.org/10.1097/MPH.0000000000002187
work_keys_str_mv AT rahimmahvishq maintenanceofanimmunogenicresponsetopneumococcalvaccinationinchildrenwithsicklecelldisease
AT arendsalexandriam maintenanceofanimmunogenicresponsetopneumococcalvaccinationinchildrenwithsicklecelldisease
AT jacobseethala maintenanceofanimmunogenicresponsetopneumococcalvaccinationinchildrenwithsicklecelldisease